NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO – Get Free Report)’s share price was up 2.6% during trading on Wednesday . The stock traded as high as $3.50 and last traded at $3.10. Approximately 39,253 shares traded hands during trading, a decline of 96% from the average daily volume of 1,065,755 shares. The stock had previously closed at $3.02.
NeuroBo Pharmaceuticals Trading Up 1.3 %
The firm has a fifty day moving average of $4.43 and a 200 day moving average of $3.96.
NeuroBo Pharmaceuticals Company Profile
NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity.
Read More
- Five stocks we like better than NeuroBo Pharmaceuticals
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- 3 Stocks Leading the U.S. Agriculture Comeback
- Canada Bond Market Holiday: How to Invest and Trade
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Breakout Stocks: What They Are and How to Identify Them
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for NeuroBo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroBo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.